Perakizumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | IL17A |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6454H9964N1718O2030S44 |
Molar mass | 145515.34 g·mol−1 |
Perakizumab (INN) is a humanized monoclonal antibody designed for the treatment of arthritis.[1] It binds to IL17A and acts as an immunomodulator.[2]
This drug was developed by Genentech/Roche.
References[]
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Perakizumab, American Medical Association.
- ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
Categories:
- Drugs not assigned an ATC code
- Monoclonal antibodies
- Monoclonal antibody stubs